Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.39 |
| ▸ | ITGAV | P06756 | 1/20 | 0.39 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 5/20 | 0.38 |
| ▸ | REN | P00797 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PEPD | P12955 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7875512 | 1.00 | RAB9A (0.47) | RAB9ATSHRALDH1A1SMN1; SMN2ITGB3 | |
| SCHEMBL9169937 | 0.88 | RAB9A (0.61) | RAB9AALDH1A1SMN1; SMN2ITGB3ITGB1 | |
| SCHEMBL9169924 | 0.88 | RAB9A (0.61) | RAB9AALDH1A1SMN1; SMN2ITGB3ITGB1 | |
| SCHEMBL31257712 | 0.88 | RAB9A (0.61) | RAB9AALDH1A1SMN1; SMN2ITGB3ITGB1 | |
| SCHEMBL9176935 | 0.86 | RAB9A (0.55) | RAB9AALDH1A1SMN1; SMN2ITGB3ITGB1 | |
| SCHEMBL21225069 | 0.86 | RAB9A (0.55) | RAB9AALDH1A1SMN1; SMN2ITGB3ITGB1 | |
| SCHEMBL10154690 | 0.83 | TSHR (0.47) | RAB9ATSHRALDH1A1MAPT | |
| SCHEMBL23854197 | 0.82 | TSHR (0.45) | RAB9ATSHRSMN1; SMN2 | |
| SCHEMBL7871571 | 0.80 | RAB9A (0.57) | RAB9ATSHRALDH1A1SMN1; SMN2ACE | |
| SCHEMBL25414655 | 0.80 | RAB9A (0.57) | RAB9ATSHRALDH1A1SMN1; SMN2ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353864-A1 | INDAZOLE CONTAINING MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250177383-A1 | DI-CYCLOPROPYL BASED IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. | 2025-06-05 | — | — | US | disclosed |
| EP-4482823-A1 | DI-CYCLOPROPYL BASED IL-17A MODULATORS AND USES THEREOF | Dice Alpha, Inc. (US) | 2025-01-01 | — | — | EP | disclosed |
| CN-119072465-A | Bicyclic propyl-based IL-17A modulators and uses thereof | 戴斯阿尔法公司 | 2024-12-03 | — | — | CN | disclosed |
| WO-2023164057-A1 | DI-CYCLOPROPYL BASED IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-09 | — | — | US | disclosed |
| EP-2601188-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-18 | — | — | EP | disclosed |
| US-20080311075-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-12-18 | — | — | US | disclosed |
| US-20080311075-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-12-18 | — | — | US | disclosed |
| US-20080299075-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-12-04 | — | — | US | disclosed |
| WO-2008144380-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-28 | — | — | US | disclosed |
| WO-2008021936-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021928-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021927-A2 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080044379-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| US-20080044380-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | HAVCR2, LIPC, PYGL | RAB9A 2545/4885TSHR 4676/4885ALDH1A1 1107/4885 |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | RAB9A 2463/4885TSHR 4635/4885ALDH1A1 1144/4885 |
| US-20250177383-A1 | DI-CYCLOPROPYL BASED IL-17A MODULATORS AND USES THEREOF | IL17A, IL23R, IL2 | RAB9A 1482/4885TSHR 4557/4885ALDH1A1 356/4885 |
| US-20080299075-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | RAB9A 2463/4885TSHR 4635/4885ALDH1A1 1144/4885 |
| US-20250353864-A1 | INDAZOLE CONTAINING MACROCYCLES AND THEIR USE | AADAC, PAICS, CYP3A43 | RAB9A 2308/4885TSHR 2901/4885ALDH1A1 2230/4885 |
| US-20080044379-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | RAB9A 2463/4885TSHR 4635/4885ALDH1A1 1144/4885 |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | RAB9A 2463/4885TSHR 4635/4885ALDH1A1 1144/4885 |
| US-20080044380-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | RAB9A 2463/4885TSHR 4635/4885ALDH1A1 1144/4885 |
| US-20080311075-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | RAB9A 2463/4885TSHR 4635/4885ALDH1A1 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.